Ion Channel Myopathies Channelopathies

Slide 1 · Ion Channel Myopathies (Channelopathies)

Molecular mechanisms, inherited phenotypes, and clinicopathologic reasoning

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning goals

Define inherited muscle channelopathies and explain their variable clinical expression.

Connect repeat-expansion RNA toxicity in myotonic dystrophy to abnormal chloride-channel expression.

Recognize the gene–phenotype patterns of periodic paralysis, myotonia, and malignant hyperthermia.

Distinguish source-supported molecular associations from findings that require further testing.

Slide 3 · Three mechanisms organize the topic

Abnormal channel function

Inherited changes in ion-channel proteins alter muscle behavior.

Repeat-expansion RNA toxicity

An expanded transcript disrupts splicing of other muscle genes.

Disordered calcium release

An altered sarcoplasmic-reticulum channel can produce a hypermetabolic crisis.

Slide 4 · What defines a channelopathy?

Inherited mutation → altered ion-channel protein function

Ion channels influence excitable tissues, including skeletal muscle.

The precise channel affected determines which organ systems may manifest disease.

The term describes a molecular mechanism, not one clinical phenotype.

Slide 5 · Inheritance pattern is informative—but not absolute

General observation

Most channelopathies are autosomal dominant.

A family history may therefore inform clinical suspicion.

“Most” does not imply that every disorder follows this pattern.

Variable penetrance

Carrying a pathogenic variant need not produce identical clinical findings in relatives.

Clinical expression can differ despite familial inheritance.

Inheritance and penetrance are distinct descriptors.

Slide 6 · Ion channels are relevant beyond skeletal muscle

Central nervous system

Epilepsy; Migraine; Movement disorders with cerebellar dysfunction

Peripheral nervous system

Peripheral nerve disease may arise with some channel defects.

Skeletal muscle

Muscle involvement is the focus of this lecture.

Slide 7 · From channel identity to phenotype

Mutated gene

Affects a particular ion-channel protein

Channel function

Functional properties are altered

Excitable tissue

Muscle or neural systems may be involved

Clinical pattern

Manifestations depend on the affected channel

This is a conceptual classification of the source description, not a single universal biochemical pathway.

Slide 8 · The skeletal-muscle phenotype spectrum

Some ion-channel myopathies reduce excitability and manifest with decreased muscle tone.

Others increase excitability and may manifest with increased tone or myotonia.

The clinical phenotype depends on which channel is disturbed.

Periodic paralysis adds an episodic weakness phenotype classified by potassium during symptoms.

Slide 9 · Two conceptual routes to myotonia

Direct channel abnormality

CLCN1 mutations are linked to myotonia congenita.

The affected protein is a skeletal-muscle chloride channel.

A channel-gene lesion is the proximal genetic abnormality.

Indirect loss of channel expression

DM1 begins with CTG-repeat expansion in DMPK.

Expanded RNA is thought to alter CLCN1 splicing.

Reduced channel expression provides a mechanistic link to myotonia.

Slide 10 · Myotonia is a clinical phenomenon

Sustained involuntary contraction of muscle

The presence of myotonia does not independently establish which gene is responsible.

Myotonic dystrophy is one multisystem disorder in which myotonia is important.

Myotonia congenita is another disorder linked to defective chloride-channel function.

Slide 11 · Myotonic dystrophy is multisystem disease

Skeletal muscle

Weakness and myotonia

Lens

Cataracts

Endocrine system

Endocrinopathy

Heart

Cardiomyopathy

Slide 12 · Clinical and genetic framing of myotonic dystrophy

Autosomal dominant inheritance is characteristic.

The Robbins text estimates an overall frequency of approximately 1 in 10,000 individuals.

Myotonic dystrophy may be grouped with dystrophies or channelopathies because of its unusual mechanism.

DM1 and DM2 have different repeat-expansion genes.

Slide 13 · DM1 and DM2: The initiating genetic events

Characteristic

Type 1 (DM1)

Type 2 (DM2)

Affected gene

DMPK

CNBP

Expanded DNA motif

CTG (trinucleotide)

CCTG (tetranucleotide)

Relationship

More common form; discussed in detail by Robbins

Mentioned as a second molecular subtype

Shared framework

Repeat-expansion disease

Repeat-expansion disease

Slide 14 · Repeat expansion is the initiating lesion in DM1

DMPK gene

Contains an expanded CTG-repeat tract

RNA transcript

Carries expanded repeat sequence

RNA-associated effect

Abnormal interactions with splicing regulators

Downstream genes

Altered alternative splicing

The text proposes a toxic RNA gain-of-function mechanism; The downstream phenotypes are not all fully explained.

Slide 15 · Repeat size does not precisely predict clinical severity

Repeat expansion length and disease severity are associated less tightly than in some other repeat disorders.

This relationship with Huntington disease.

Severe congenital myotonic dystrophy is typically linked to larger expansions.

Do not treat expansion size as a standalone deterministic severity measure.

Slide 16 · Genetic association versus mechanistic certainty

Supported observations

DM1 originates from CTG expansion in DMPK.

Abnormal transcripts contain expanded repeat material.

Alternative splicing of several genes is affected.

Proposed explanation

Experimental findings suggest toxic RNA gain-of-function.

Sequestration of splicing regulators is the proposed intermediate.

Different mis-spliced genes may explain different system manifestations.

Slide 17 · Toxic RNA gain-of-function: Proposed sequence

Repeat-containing RNA

Abnormal expanded CTG-repeat transcript

Splicing regulators

Bind and are sequestered by the transcript

Alternative splicing

Processing of selected RNAs becomes abnormal

Muscle phenotype

Defective channel expression contributes to myotonia

The words “suggest,” “appear,” and “thought” reflect the source’s uncertainty language.

Slide 18 · Why a repeat expansion can act through RNA

The toxic species is proposed to be the expanded transcript

A genetic expansion can alter cell function without simply deleting a protein.

Expanded RNA is proposed to bind proteins that normally regulate RNA splicing.

Abnormal splicing can change the function or abundance of several downstream proteins.

Slide 19 · Splicing regulators link one mutation to many effects

Initiating event

Expanded DMPK RNA accumulates.

Shared cellular process

Muscle RNA-splicing regulation is disrupted.

Multiple downstream targets

CLCN1 and insulin receptor isoforms are specifically mentioned.

Slide 20 · How DM1 RNA toxicity produces myotonia

DMPK CTG expansion

Expanded RNA repeat sequence

Splicing dysregulation

CLCN1 RNA is abnormally spliced

Chloride channel

CLCN1 channel expression decreases

Clinical manifestation

Myotonia becomes prominent

This causal chain is based on the mechanism proposed; Reduced channel expression is not itself a DM1 mutation in CLCN1.

Slide 21 · CLCN1: One gene, two disease mechanisms

CLCN1 encodes a chloride channel.

In myotonia congenita, the causative mutation affects CLCN1 itself.

In DM1, the initiating lesion is a DMPK repeat expansion, with decreased CLCN1 expression downstream.

Identical clinical terms can conceal very different levels of molecular abnormality.

Slide 22 · Myotonic dystrophy versus myotonia congenita

Dimension

Myotonic dystrophy (DM1)

Myotonia congenita

Initiating molecular event

DMPK CTG repeat expansion

CLCN1 mutation

CLCN1 relevance

Reduced expression from altered splicing

Channel gene itself is affected

Disease context

Multisystem: muscle, lens, endocrine, heart

Source links directly to myotonia

Molecular category

Toxic RNA gain-of-function proposed

Ion-channel gene disorder

Slide 23 · Endocrine phenotype: A second splicing example

Insulin resistance and diabetes are described among possible DM1 consequences.

Them to alternative splicing of insulin-receptor isoforms in skeletal muscle.

The text presents this relationship as a possible mechanism, not as a complete causal proof.

This illustrates how RNA-processing dysregulation can extend beyond myotonia.

Slide 24 · Muscle RNA splicing and endocrine effects

Expanded DMPK RNA

Proposed toxic gain-of-function

Splicing regulators

Sequestered by expanded transcripts

Insulin receptor RNA

Isoform usage may be altered

Metabolic phenotype

Insulin resistance or diabetes may result

Cautious wording: The endocrine link “may be” caused by alternative splicing.

Slide 25 · One repeat expansion; Several target systems

Motor manifestations

Weakness and myotonia

Ocular manifestation

Cataracts

Endocrine manifestations

Endocrinopathy; Possible insulin resistance or diabetes

Cardiac manifestation

Cardiomyopathy

Slide 26 · What is not fully resolved in DM1 pathogenesis?

A single affected splice target does not fully explain the multisystem phenotype.

The source mentions differential expression of additional genes.

Accumulation of repeat-containing transcripts may contribute to other manifestations.

Clinical interpretation should distinguish established genotype from proposed downstream biology.

Slide 27 · Applied reasoning: Multisystem myotonia

CLINICAL REASONING EXERCISE

A patient has muscle weakness and sustained involuntary muscle contraction, with cataracts and cardiomyopathy.

Which disease category best unifies these findings?

Myotonic dystrophy; The combined muscle, ocular, and cardiac findings match its multisystem description.

Slide 28 · Applied reasoning: Primary versus secondary channel lesion

CLINICAL REASONING EXERCISE

A genetic report identifies a DMPK CTG-repeat expansion, and the patient has myotonia.

Is the initiating lesion necessarily a mutation in the CLCN1 gene?

No. The source proposes abnormal CLCN1 splicing and reduced channel expression downstream of DMPK RNA toxicity.

Slide 29 · Other ion-channel myopathies

Altered excitability can produce weakness or myotonia

The next set of disorders is organized by ion channel, phenotype, and—in periodic paralysis—serum potassium during symptoms.

Slide 30 · Excitability abnormalities: Two directions

Reduced excitability

May be associated with hypotonia.

Episodic weakness is the defining clinical context of periodic paralysis.

Potassium status during symptoms provides a further subclassification.

Increased excitability

May be associated with hypertonia or myotonia.

The sodium- and chloride-channel disorders include myotonic phenotypes.

Channel behavior and presentation are gene-dependent.

Slide 31 · Periodic paralysis is classified during symptoms

Serum potassium level distinguishes the named subgroups

Hyperkalemic periodic paralysis: Elevated serum potassium during symptoms.

Hypokalemic periodic paralysis: Depressed serum potassium during symptoms.

Normokalemic periodic paralysis: Normal serum potassium during symptoms.

Slide 32 · Periodic paralysis: Three potassium-defined labels

Hyperkalemic

Elevated serum potassium when symptomatic

Hypokalemic

Depressed serum potassium when symptomatic

Normokalemic

Normal serum potassium when symptomatic

Slide 33 · Potassium terminology is descriptive, not genetic

Label

Serum potassium during symptoms

What the label alone establishes

Hyperkalemic

Elevated

A biochemical subgroup

Hypokalemic

Depressed

A biochemical subgroup

Normokalemic

Normal

A biochemical subgroup

Gene assignment

Requires molecular context

Cannot be read from potassium alone

Slide 34 · Channel genes highlighted by Robbins

KCNJ2

Potassium channel; Andersen–Tawil syndrome

SCN4A

Sodium channel; Myotonia or paralysis

CACNA1S

Calcium-channel subunit; Hypokalemic paralysis

CLCN1

Chloride channel; Myotonia congenita

RYR1

Calcium release from sarcoplasmic reticulum

Slide 35 · Interpreting a gene–phenotype association

Genetic result

Identify implicated gene

Channel identity

Potassium, sodium, calcium, chloride or SR receptor

Recognized syndrome

Use phenotype associations in the text

Clinical consequences

Consider muscle and relevant other organs

Associations support differential diagnosis; The excerpt does not supply a standalone genetic testing protocol.

Slide 36 · KCNJ2 identifies a potassium-channel syndrome

KCNJ2 mutations affect a potassium-channel protein.

The described phenotype is Andersen–Tawil syndrome.

Periodic paralysis is one component of the disorder.

Cardiac arrhythmias and skeletal abnormalities are additional defining features.

Slide 37 · Andersen–Tawil syndrome: Clinical triad

Muscle

Periodic paralysis

Heart

Cardiac arrhythmias

Skeleton

Skeletal abnormalities

Slide 38 · Cardiac involvement changes clinical interpretation

Periodic paralysis plus arrhythmias suggests a multisystem channel disorder

KCNJ2-associated Andersen–Tawil syndrome involves both skeletal and cardiac manifestations.

The same patient cannot be understood exclusively through a muscle complaint.

This is a syndrome-level association, not a claim about the specificity of any isolated symptom.

Slide 39 · Applied reasoning: Paralysis plus extra-muscle findings

CLINICAL REASONING EXERCISE

A patient has episodes of paralysis together with cardiac arrhythmias and skeletal abnormalities.

Which gene–syndrome pair is most relevant in the source?

KCNJ2 and Andersen–Tawil syndrome.

Slide 40 · SCN4A: One sodium-channel gene, several presentations

SCN4A encodes a skeletal-muscle sodium channel.

Mutations are linked to multiple autosomal disorders.

Presentations range from myotonia to periodic paralysis.

A gene label does not imply one uniform clinical phenotype.

Slide 41 · SCN4A connects hyperexcitability and weakness

Myotonic presentation

The phenotype includes sustained involuntary muscle contraction.

This lies on the increased-excitability side of the source framework.

SCN4A is explicitly linked to myotonia.

Paralytic presentation

Periodic paralysis is another documented SCN4A-associated manifestation.

Weakness can be episodic.

The source does not assign every SCN4A variant to a potassium subgroup.

Slide 42 · CACNA1S and hypokalemic periodic paralysis

CACNA1S encodes a subunit of a muscle calcium channel.

Missense mutations in this gene are implicated in hypokalemic paralysis.

CACNA1S as the most common genetic cause of hypokalemic paralysis.

This gene-level statement should not be generalized to every periodic-paralysis subtype.

Slide 43 · CACNA1S: Separating protein and phenotype

CACNA1S

Missense variant

Muscle calcium channel

Affected channel subunit

Muscle phenotype

Hypokalemic periodic paralysis

Classification

Low potassium during symptoms

This is the gene–phenotype relationship stated; No treatment pathway is inferred.

Slide 44 · CLCN1 and congenital myotonia

CLCN1 encodes a chloride channel.

Direct mutations in CLCN1 cause myotonia congenita.

DM1 can produce decreased expression of this same channel via RNA-splicing disturbance.

The distinction is between a mutated channel gene and secondary expression loss.

Slide 45 · Sodium, calcium, and chloride channel disorders

Gene

Channel type

Clinical association

SCN4A

Sodium

Myotonia through periodic paralysis

CACNA1S

Muscle calcium-channel subunit

Most common cause of hypokalemic paralysis

CLCN1

Chloride

Myotonia congenita

Slide 46 · RYR1 and calcium-release disease

The sarcoplasmic-reticulum calcium channel links structure and acute physiology

RYR1-related disorders span a congenital structural myopathy and anesthetic-triggered malignant hyperthermia.

Slide 47 · RYR1 regulates sarcoplasmic-reticulum calcium release

RYR1 encodes the ryanodine receptor.

The receptor regulates calcium release from the sarcoplasmic reticulum.

RYR1 mutations disrupt normal receptor function.

The source links RYR1 to central core disease and malignant hyperthermia.

Slide 48 · The calcium-release compartment

Sarcoplasmic reticulum

Intracellular calcium store

Ryanodine receptor

RYR1 protein regulates release

Calcium efflux

Can increase abnormally after trigger

Muscle physiology

Tetany and excessive heat may follow

Native conceptual diagram; It does not represent molecular structure or actual calcium flux measurements.

Slide 49 · One RYR1 gene: Two source-described outcomes

Central core disease

Congenital skeletal-muscle myopathy.

Associated with certain RYR1 mutations.

The parent inherited-myopathy section describes central core morphology.

Malignant hyperthermia

An acute hypermetabolic state.

Can be triggered by specific anesthetic exposures.

Abnormal receptor-mediated calcium efflux is the proposed proximal event.

Slide 50 · Central core disease as inherited-myopathy context

Central core disease is listed among congenital myopathies.

Mutations in RYR1 are one molecular cause.

The parent Robbins table describes cytoplasmic cores with disrupted sarcomeres and fewer mitochondria.

Not every RYR1-associated phenotype is necessarily malignant hyperthermia.

Slide 51 · Malignant hyperthermia is an anesthetic-triggered crisis

RYR1 dysfunction → excess calcium release after an anesthetic trigger

The response is described as a hypermetabolic state.

The text emphasizes halogenated inhalational anesthetics and succinylcholine as triggers.

Muscle tetany and excess heat production follow abnormal calcium efflux.

Slide 52 · Triggers highlighted

Halogenated inhalational agents

A commonly implicated class of anesthetic triggers

Succinylcholine

A triggering agent specifically named in the section

Susceptible receptor

The abnormal response occurs in the context of an affected RYR1 channel

Slide 53 · Pathogenesis of malignant hyperthermia

Anesthetic exposure

Halogenated agent or succinylcholine

Altered RYR1

Abnormal sarcoplasmic-reticulum channel behavior

Increased calcium efflux

Excess calcium leaves the SR

Tetany and heat

Muscle spasms and excessive heat production

A schematic presentation of the sequence explicitly described in the source.

Slide 54 · Malignant hyperthermia: Clinical time course

Early features

Tachycardia, tachypnea and muscle spasms

Later feature

Hyperpyrexia is described as occurring later

Underlying state

Marked hypermetabolism associated with abnormal calcium release

Slide 55 · Malignant hyperthermia: Trigger versus manifestation

Initiating context

Exposure to a named triggering anesthetic.

Underlying mutation affects calcium-release regulation.

Excess efflux is the immediate channel abnormality.

Resulting clinical picture

Tetany and muscle spasms.

Tachycardia and tachypnea.

Excessive heat production and later hyperpyrexia.

Slide 56 · Applied reasoning: Anesthetic-triggered muscle crisis

CLINICAL REASONING EXERCISE

Following exposure to an inhalational anesthetic, a patient develops tachycardia, tachypnea, and sustained muscle spasms; Hyperpyrexia develops later.

What molecular process is emphasized by the textbook?

RYR1-associated excess calcium efflux from the sarcoplasmic reticulum following an anesthetic trigger.

Slide 57 · Gene–channel–phenotype reference matrix

Gene

Protein / channel

Main relationship in Robbins

KCNJ2

Potassium channel

Andersen–Tawil: paralysis, arrhythmia, skeletal changes

SCN4A

Sodium channel

Myotonia to periodic paralysis

CACNA1S

Muscle calcium-channel subunit

Hypokalemic paralysis

CLCN1

Chloride channel

Myotonia congenita; reduced in DM1

RYR1

SR calcium-release receptor

Central core disease; malignant hyperthermia

Slide 58 · Phenotype-first comparison of channel disorders

Presentation

Best-fitting source associations

Interpretive caution

Myotonia

DM1; CLCN1; some SCN4A

Several initiating mechanisms

Periodic paralysis

KCNJ2; SCN4A; CACNA1S

Determine symptomatic K category

Paralysis + arrhythmia

KCNJ2 / Andersen–Tawil

Look beyond the muscle

Anesthetic hypermetabolism

RYR1 / malignant hyperthermia

Specific clinical emergency phenotype

Congenital core myopathy

Certain RYR1 mutations

Not equivalent to anesthetic crisis

Slide 59 · Phenotype-oriented classroom reasoning pathway

Main presentation

Myotonia, paralysis or anesthetic crisis?

Supporting context

Multisystem signs and potassium pattern

Gene candidates

DM1, CLCN1, SCN4A, KCNJ2, CACNA1S or RYR1

Molecular model

Separate direct channel mutation from downstream expression change

Teaching heuristic synthesized from textbook associations; Not a clinical diagnostic algorithm or validated testing rule.

Slide 60 · Important scope boundaries for diagnosis

The supplied excerpt provides genotype–phenotype associations, not detailed confirmatory test criteria.

It does not provide variant-interpretation rules, electrodiagnostic thresholds, or test performance.

It does not provide pharmacologic treatment regimens for periodic paralysis or malignant hyperthermia.

These omissions should not be replaced with unverified numerical claims.

Slide 61 · Channelopathies versus metabolic myopathies

Ion-channel myopathies

The organizing defect is altered channel function or channel expression.

Typical presentations include myotonia and periodic paralysis.

RYR1 is linked to anesthetic-triggered calcium dysregulation.

Adjacent metabolic-myopathy context

Inherited defects in lipid or glycogen handling affect muscle.

The next Robbins heading mentions exercise- or fasting-associated cramping, pain and rhabdomyolysis.

Some forms cause progressive weakness instead.

Comparison is limited to distinctions stated in the supplied adjacent Robbins text.

Slide 62 · Applied reasoning: Naming the potassium subgroup

CLINICAL REASONING EXERCISE

An individual experiences an episode of periodic paralysis. The serum potassium concentration obtained during symptoms is below the normal interval.

Which descriptive subgroup applies?

Hypokalemic periodic paralysis. Potassium status alone does not identify the causal gene.

Slide 63 · Applied reasoning: Gene and mechanism matching

CLINICAL REASONING EXERCISE

In a teaching exercise, pair each disease mechanism with a source-described gene: Toxic repeat RNA, primary chloride channel defect, and abnormal SR calcium release.

Which three gene labels are expected?

DMPK (DM1); CLCN1 (myotonia congenita); RYR1 (calcium-release disorders).

Slide 64 · Five clinically useful discriminators

Repeat expansion

DMPK for DM1; CNBP for DM2

Symptomatic potassium

Hyper-, hypo-, or normokalemic paralysis

Arrhythmia + skeleton

Andersen–Tawil / KCNJ2

Myotonia alone

Consider more than one genetic pathway

Anesthetic crisis

RYR1-associated malignant hyperthermia

Slide 65 · Integrated mechanism summary

Muscle channelopathies form a mechanistically diverse inherited disease group.

DM1 involves proposed RNA-mediated splicing dysfunction with reduced CLCN1 expression.

Primary channel-gene variants can produce myotonia, periodic paralysis, or syndromic features.

RYR1 can connect congenital muscle pathology and anesthetic-triggered calcium dysregulation.

Slide 66 · References and source limitations

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th edition (2026), Chapter 27, p. 1123; primary lecture source.

The inherited-myopathy discussion and adjacent metabolic-myopathy text were used only for bounded conceptual context.

Source available for production: original-text Markdown extraction and topic Markdown; chapter PDF pages and licensed textbook figures were not supplied.

All molecular diagrams, comparison tables, and teaching vignettes are original editable teaching constructs—not experimental data or patient specimens.